ONE for ASPIRE

We are announcing the One for ASPIRE campaign!

Our goal is for each site to CONSENT 1 PATIENT for ASPIRE before the end of 2021.

With your help we have learned how to overcome obstacles to enrolling ICH patients with AF, a target population of relatively rare patients who often have more severe impairments than a typical trial participant.

Although challenging, we know that all ASPIRE investigators are committed to finding the best approach to treating these patients.

Together we can make this happen!

Please join us for the ASPIRE Monthly Webinar

Wednesday September 22 3:00-4:00 pm ET

Topics will include the **challenges of transitions of care** and how to make ASPIRE a platform **for better care for ICH patients**.

To join Zoom Meeting -- Meeting ID: 995 2558 8890 Passcode: 317043, or call in. To find your local number, go to https://ucincinnati.zoom.us/u/ap5xbnzhb

Recruitment Update

ASPIRE PARTICIPANTS: 41

Since last newsletter...

Randomizations

North Shore University Hospital 1
OU Medical Center 1
Yale New Haven Hospital 1

Welcome to our New Sites!

Baystate Medical Center
Desert Regional Medical Center
Kevin Attenhofer (PI), Claudia Fortiche (PSC)
Darwin Ramirez Abreu (PI), David Bachman (PSC)
Los Alamitos Medical Center
Nirav Patel (PI), Richard Bailey (PSC)
NYP Columbia University
Imama Naqvi (PI), Alberto Canaan (PSC)
Regions Hospital
Darwin Ramirez-Abreu (PI), David Bachman (PSC)
Vivek Rai (PI), Heather Bartelt (PSC)

Congratulations to

North Shore University Hospital

OU Medical Center

for their 1st Randomizations!





Tania Rebeiz (PI)


Melinda Harbhajan and Sarah Nazir (SC) [not pictured]






Evgeny Sidorov (PI)

Blair Apple and April Vaughan (SC)







■ SINCE LAST NEWSLETTER

Revised Forms Posted in WebDCU

<u>Concomitant Medication Checklist</u> (F303) – Medications have been revised to align with current protocol and this form is now to be used at **all subject visits**.

- At Screening, record medication use within 7 days prior to ICH.
- At Baseline, record medication use at time of initiation of study drugs.
 - **If subject was taking anticoagulants or antiplatelets at the time of randomization but had not taken these medications within 12 hours of the first dose of study drugs (as per protocol), note use as 'No'.**
- At Follow-up, record use at time of the visit.

<u>Prior Medications (F306)</u> form has been deactivated and data entered on that form have been transferred to F303 at Screening.

End of Study (F126) – Date of ICH onset has been added to this form to facilitate reimbursement for consenting a subject within 14 days of the index event.

ASPIRE Site Study Drug Procedures v3 posted

Major change: Since very few subjects meet criteria for 2.5mg study drug, only the (2) kits for 5mg study drug arms will be provided for site inventory; see manual for procedures for provision of study drug kits to participants meeting criteria for 2.5 study drug.

Spanish Language PATIENT VIDEO

Recruitment video is now available in Spanish to share with your patients and their families.

https://youtu.be/AmGkT6jaluw https://www.nihstrokenet.org/aspire-trial/home



ASPIRE CONTACT INFORMATION 24/7 Hotline: (800) 618-0643 ASPIRE@YALE.EDU

Principal Investigators

Kevin Sheth, Yale University; kevin.sheth@yale.edu Hooman Kamel, Weill Cornell Medicine; hok9010@med.cornell@edu

NCC ASPIRE Project Manager

Laura Benken aspire@yale.edu (513) 558-3925

Yale ASPIRE Project Lead

Catherine Viscoli catherine.viscoli@yale.edu (203) 927-0443